-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Neutral on Intellia Therapeutics, Raises Price Target to $13

Benzinga·09/09/2026 12:19:12
语音播报
Wedbush analyst David Nierengarten maintains Intellia Therapeutics (NASDAQ:NTLA) with a Neutral and raises the price target from $12 to $13.